Johns Hopkins All Children's Hospital
St. Petersburg, Florida, 33701, United States
NCT Number: NCT04246333
Premature infants have high rates of bronchopulmonary dysplasia (BPD) due to prematurity of the participants' lungs and the need for prolonged respiratory support. These infants are at increased risk for gastroesophageal reflux and aspiration which may exacerbate lung injury. Transpyloric feeds, specifically duodenal feeds, may be used to bypass the stomach and directly feed the duodenum decreasing the amount of gastric reflux contributing to aspiration. Duodenal feeds are equivalent to gastric feeds with regards to nutritional outcomes, and have been shown to decrease events of apnea and bradycardia in premature infants. This study will evaluate the feasibility and safety of duodenal feeds in premature infants. The hypothesis is that duodenal feeds may be safely and successfully performed in premature very low birth weight infants.
Looking for future studies?
Notify Me0 day–12 month
All sexes
Interventional
Not applicable
St. Petersburg, Florida, 33701, United States
The primary outcome of this study is the safety and feasibility of duodenal feeds in very low birth weight infants. The secondary outcomes are various measures related to growth, respiratory support, comorbidities, and hospitalization.
Eligibility of infants admitted to the Johns Hopkins All Children's Neonatal Intensive Care Unit (NICU) will be determined based on inclusion and exclusion criteria. Eligible infants will be recruited and enrolled by 14 days of life after informed consent is obtained. Randomization of the infants into two groups- investigational continuous Duodenal Feeds (DF) or standard Gastric Feeds (GF) - will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds.
All enrolled infants will be fed per the institutional feeding protocol. Once infants advance past 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups in a 1:1 block randomization using blinded envelopes. Multiple gestation infants will be randomized individually.
Placement of gastric tubes will be per standard of practice, and insertion of duodenal tube will be per manual of operations. Continuous duodenal feeds will be provided over 24 hours as a continuous infusion through a nasoduodenal or oro-duodenal tube. Standard gastric feeds will be infused via a nasogastric or orogastric tube per the instructions of the medical team. Gastric feeds are provided as standard of care in the NICU; intermittent bolus feeds over 15-60 minutes. Feeding time may be prolonged by the medical team, for longer than 60 minutes and possibly even be given continuously, for various reasons (emesis, reflux, apnea, bradycardia, etc.) and will be monitored and recorded. Feed volume and advancement will continue to be determined by standardized institutional feeding guidelines. Decision to provide further fortification of feeds beyond institutional guidelines will be determined by the medical team and not standardized in this protocol. Once full enteral feeds are achieved (total fluid goal of at least 140mL/kg/day), patients will continue to receive feeds via the designated route.
An institutional "Infant Driven Feeding Guideline" is utilized to evaluate readiness to orally feed and to transition premature infants from enteral to oral feeds. Once an infant is eligible to receive oral feeds per this guideline (32 weeks postmenstrual age, and tolerating ≤2L flow via nasal cannula for at least 24 hours), the study will allow the medical team to transition infants in the DF group to gastric feeds. Regarding transitioning infant from duodenal to gastric feeds, infants are initially placed on continuous gastric feeds, and once the participants have demonstrated tolerance (no evidence of reflux, increased respiratory support, emesis), the participants are then transitioned to bolus gastric feeds progressively. Infants may be allowed to orally feed during this transition period if the participants meet the appropriate infant driven feeding scores per protocol.
All infants in this study will be monitored for primary and secondary outcomes through the duration of admission and up until the time of discharge. Safety events will be frequently monitored for throughout the duration of admission and addressed immediately if warranted.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
Time frame: 12 months
Success to be measured by appropriate placement of the duodenal tube within the duodenum as confirmed by radiographic imaging.
Time frame: 12 months
Safety of duodenal feeds in very low birth weight infants as measured by the number of intestinal perforations secondary to placement of duodenal tube.
Time frame: duration of hospitalization, up to 15 months
Number of days on supplemental oxygen >21% throughout duration of hospitalization
Time frame: 15 months
Mild, moderate, severe Bronchopulmonary Dysplasia (BPD) as defined by the NICHD/NHLBI/ORD Workshop published in 2001
Time frame: 15 months
Time frame: 15 months
Days of invasive mechanical ventilation up until hospital discharge
Time frame: 15 months
Number of participants diagnosed with Culture-positive sepsis after 72 hours of life
Time frame: 15 months
Cumulative days of indwelling central venous catheters (peripherally inserted central catheters, tunneled venous catheters, umbilical venous catheters)
Time frame: 15 months
Number of participants with necrotizing enterocolitis (NEC) defined by Modified Bells Stage II or greater
Time frame: 15 months
Number of replaced enteral tubes, gastric or duodenal, per patient
Time frame: 15 months
Number of radiographs obtained with the indication of enteral tube placement, gastric or duodenal
Time frame: At 36 weeks
Weight percentile at 36 weeks postmenstrual age
Time frame: At 36 weeks
Height percentile at 36 weeks postmenstrual age
Time frame: At 36 weeks
Head circumference percentile at 36 weeks postmenstrual age
Time frame: At 36 weeks
Z-scores for weight at 36 weeks postmenstrual age calculated using PediTools
Time frame: At 36 weeks
Z-scores for height at 36 weeks postmenstrual age calculated using PediTools
Time frame: At 36 weeks
Z-scores for head circumference at 36 weeks postmenstrual age calculated using PediTools
Time frame: At 36 weeks
Average daily weight gain (kg/day) calculated from birth until 36 weeks postmenstrual age using the fetal-infant growth reference (FIGR) equation
Time frame: duration of hospitalization, up to 15 months
Length of hospital stay (days)
Time frame: 15 months
Number of participants requiring fortification beyond 24kcal/oz
Time frame: 15 months
Number of participants requiring use of postnatal dexamethasone for respiratory indications
Time frame: 15 months
Number of participants requiring use of chronic diuretics including thiazide diuretics and spironolactone
Johns Hopkins All Children's Hospital
Other
Feasibility and Safety of Duodenal Feeds in Very Low Birth Weight Infants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03242057
BPD - Bronchopulmonary Dysplasia, Barotrauma
Jacksonville, Florida, United States
View Trial DetailsNCT07418502
BPD - Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia
San Diego, California, United States
View Trial DetailsNCT06788470
BPD - Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia
Hangzhou, Zhejiang, China
View Trial DetailsNCT04971694
BPD - Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia
Phoenix, Arizona, United States
View Trial Details